Aquestive Therapeutics Q1 Revenue Soars Past Estimates by 32% to $14.4 Million
summarizeSummary
Aquestive Therapeutics reported first-quarter revenue of $14.446 million, significantly surpassing the IBES consensus estimate of $10.9 million by approximately 32%. This substantial revenue beat is a material positive development, especially following the company's reported increase in net loss for 2025 and FDA approval delays for Anaphylm, as highlighted in its recent 10-K filing. The stronger-than-expected top-line performance could indicate improving commercial traction for its products. Traders will be watching closely to see if this revenue momentum can be sustained and how it impacts the company's overall financial trajectory, particularly given the continued negative income from operations and net income reported for the quarter.
At the time of this announcement, AQST was trading at $4.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $513.3M. The 52-week trading range was $2.12 to $7.55. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.